NCT Number: NCT00191841
Gemcitabine in Combination With Cisplatin as Neoadjuvant NSCLC Chemotherapy
To evaluate the clinical response rate of neoadjuvant chemotherapy with gemcitabine and cisplatin in patients with operable NSCLC
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–65 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Primary location
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Barnaul, Russia
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- histologic or cytologic diagnosis of operable non-small cell lung cancer (IB-IIIA)
- no prior chemotherapy
- WHO criteria for disease status assessment
Exclusion criteria
- Concurrent administration of any other tumor therapy
- pregnant or breast feeding
- serious concomitant disorders
Treatment and study plan
Cisplatin
DrugPrimary outcomes
-
Antitumor activity
Secondary outcomes
-
Duration of response, time to progressive disease, time to treatment failure
Sponsors and collaborators
Lead sponsor
Eli Lilly and Company
Industry
Registry information
Official study title
Gemcitabine Plus Cisplatin as Neoadjuvant Chemotherapy in Operable Non Small Cell Lung Cancer
Important dates
- Study start
- 2002
- Study completion
- 2006
- First posted
- Sep 19, 2005
- Registry last updated
- Jul 24, 2006
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer
NCT04838548
Bronchial Neoplasms, Carcinoma, Bronchogenic
Beijing, Beijing Municipality, China
View Trial DetailsStudy of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)
NCT05298423
Bronchial Neoplasms, Carcinoma, Bronchogenic
Long Beach, California, United States
View Trial DetailsTesting of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®.
NCT01652469
Bronchial Neoplasms, Carcinoma, Bronchogenic
Vienna, Austria
View Trial DetailsA Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment
NCT05241834
Bronchial Neoplasms, Carcinoma, Bronchogenic
Los Angeles, California, United States
View Trial Details